Optimized Single-Core PCF-Based SPR Biosensor for High-Performance Early-Stage Multi-Cancer Detection

TL;DR

This paper introduces a highly sensitive, optimized single-core PCF-based SPR biosensor that significantly improves early-stage multi-cancer detection by achieving high wavelength sensitivities and stability through innovative design and simulation.

Contribution

The study presents a novel SPR biosensor integrating a circular-lattice PCF with a V2O5 layer, enhancing sensitivity and stability for early multi-cancer detection, validated through FEM simulations.

Findings

Achieved wavelength sensitivities up to 103,571 nm/RIU for adrenal gland cancer

Maximum FOM of 306.424 RIU^-1 indicating high detection efficiency

Spectral resolution of 9.57x10^-7 RIU demonstrating precise sensing

Abstract

In this study, we present a highly sensitive Surface Plasmon Resonance (SPR)-based biosensor integrated with a circular-lattice Photonic Crystal Fiber (PCF) for early-stage cancer detection. The proposed sensor leverages the synergy between SPR and PCF technologies to overcome the bulkiness and limited sensitivity of traditional SPR systems. A thin gold (Au) layer, responsible for plasmon excitation, is deposited on the fiber structure, while a nanolayer of vanadium pentoxide (V2O5) is introduced to enhance adhesion between the gold and the silica background, improving structural stability and field confinement. The sensor is designed to detect refractive index (RI) variations in biological analytes, specifically targeting cancerous cells from skin, blood, and adrenal gland tissues. The optical characteristics and performance of the sensor were thoroughly analyzed using the Finite Element Method (FEM) in COMSOL Multiphysics 6.1, allowing for precise simulation and optimization. The sensor demonstrates high sensitivity within the RI range of 1.360-1.395, corresponding to the RI values of the target cancer cells. Remarkable wavelength sensitivities of 21,250 nm/RIU, 53,571 nm/RIU, and 103,571 nm/RIU were achieved for skin, blood, and adrenal gland cancers, respectively. In addition, a maximum figure of merit (FOM) of 306.424 RIU^-1 and a spectral resolution (SR) of 9.57x10^-7 RIU further affirm the sensor's exceptional detection capabilities. These findings indicate the proposed SPR-PCF sensor's strong potential for real-time, label-free biosensing applications, particularly in precise and early cancer diagnostics.